Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Avidity Biosciences Inc (NQ: RNA )

43.25 +0.69 (+1.62%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Avidity Biosciences Inc

< Previous 1 2 3 4 5 6 Next >
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
The company is now pivoting its technology to the cardiovascular space under a partnership with Bristol Myers Squibb. 
Via Investor's Business Daily
Assessing Avidity Biosciences: Insights From 10 Financial Analysts
Via Benzinga
In-Depth Examination Of 10 Analyst Recommendations For Avidity Biosciences
Via Benzinga
Evaluating Avidity Biosciences: Insights From 10 Financial Analysts
Via Benzinga
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Unveiling 7 Analyst Insights On Avidity Biosciences
Via Benzinga
Deep Dive Into Avidity Biosciences Stock: Analyst Perspectives (10 Ratings)
Via Benzinga
The Analyst Landscape: 7 Takes On Avidity Biosciences
Via Benzinga
Why Avidity Biosciences Zoomed to a 12% Gain This Week
The company's most promising pipeline program can continue unabated. 
Via The Motley Fool
Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases
Goldman Sachs has initiated coverage on Avidity Biosciences with a Buy rating and a $59 price target, citing multi-blockbuster commercial opportunities for its RNA therapeutics in muscular... 
Via Benzinga
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystrophy, boosting the price target from $5 to $10 due to increased confidence in... 
Via Benzinga
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials. 
Via MarketBeat
RNA Stock Earnings: Avidity Biosciences Beats EPS, Misses Revenue for Q2 2024
RNA stock results show that Avidity Biosciences beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
(RNA) - Analyzing Avidity Biosciences's Short Interest
Via Benzinga
Chart Of The Day: Avidity Biosciences - Something's Up?
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. 
Via Talk Markets
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
Via Benzinga
How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics
The company is coming up fast with a platform that could take on several of Sarepta's approved treatments. 
Via Investor's Business Daily
3 Stocks Doing Even Better Than Superstar Super Micro (SMCI)
These three stellar, outperforming stocks are doing better than even Super Micro Computer, which has been running away from the market. 
Via InvestorPlace
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
These three small-cap stocks could deliver hefty returns if the central bank cuts rates. 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins. 
Via Benzinga
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while utilities lagged. 
Via Benzinga
Topics ETFs
Trading SMID Biotech Stocks In A Volatile Market
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio?
Top mid-cap performers: Avidity Biosciences, Iris Energy, Hims & Hers Health, John Wiley & Sons, Element Solutions, CleanSpark, Enovix Corp, Axcelis Tech, Intellia Therapeutics, Korn Ferry. 
Via Benzinga
Adobe, Avidity Biosciences And 3 Stocks To Watch Heading Into Friday
Via Benzinga
Crude Oil Moves Higher; Vera Bradley Shares Slide
Via Benzinga
Exposures Fossil Fuels
Why Streamline Health Solutions Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Nasdaq Jumps 300 Points; Oracle Shares Spike Higher
Via Benzinga
Why Avidity Biosciences Shares Are Trading Higher Wednesday
The 39 patient trial was in relation to treating facioscapulohumeral muscular dystrophy (FSHD) with delpacibart braxlosiran. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback